Home » Stocks » LGVN

Longeveron, Inc. (LGVN)

Stock Price: $6.83 USD -0.17 (-2.43%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 117.80M
Revenue (ttm) 6.29M
Net Income (ttm) -2.84M
Shares Out 17.25M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $6.83
Previous Close $7.00
Change ($) -0.17
Change (%) -2.43%
Day's Open 7.00
Day's Range 5.91 - 7.30
Day's Volume 258,169
52-Week Range 5.91 - 10.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 week ago

Longeveron Inc (NASDAQ: LGVN) completes Phase 1 study of Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS). Full results from the study will be released in Q2 2021.

GlobeNewsWire - 2 weeks ago

MIAMI, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-rela...

GlobeNewsWire - 2 weeks ago

MIAMI, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-rela...

GlobeNewswire - 3 weeks ago

Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing...

NASDAQ - 1 month ago

Longeveron, a Phase 2 biotech developing cellular therapies for aging-related conditions, filed on Tuesday with the SEC to raise up to $30 million in an initial public offering.

SEC - 1 month ago

Longeveron, Inc. has filed to go public with an IPO on the NASDAQ.

About LGVN

Longeveron, a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplast... [Read more...]

Industry
Research and Development in Biotechnology
IPO Date
Feb 12, 2021
CEO
Geoff Green
Employees
16
Stock Exchange
NASDAQ
Ticker Symbol
LGVN
Full Company Profile

Financial Performance

In 2019, Longeveron's revenue was $5.82 million, an increase of 166.84% compared to the previous year's $2.18 million. Losses were -$2.96 million, -53.29% less than in 2018.

Financial Statements